Shuttle Pharmaceuticals (Nasdaq: SHPH)

We are a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy.

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Today we shared a corporate update covering our second quarter and Phase 2 clinical trial of Ropidoxuridine for glioblastoma.

We are encouraged by the progress in our Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with 63% enrollment having recently been achieved. Importantly, 72% of enrolled patients have completed all seven cycles with treatment reported as being well-tolerated. We are working closely with our primary third-party CRO, TheradexSystems, to continue execution of the clinical trial in combination with leading cancer centers across the U.S. Our goal continues to remain completion of enrollment later this year, with follow-up and data readouts anticipated in 2026.

Read our press release for more details: https://t.co/NYuxaLjipg

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Dr. Tyvin Rich is Chief Medical Officer at Shuttle Pharma, leading the clinical development of innovative radiation sensitizers to advance cancer care.

He has authored over 200 scientific publications and played a key role in pioneering RTOG clinical trials that shaped treatment approaches for rectal and pancreatic cancers.

Learn more about our team: https://t.co/yvMbOpZecw

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

As a Scientific Advisor to Shuttle Pharma, Dr. Armstrong brings deep expertise in process chemistry, drug development, and large-scale manufacturing.

He is best known for leading the team that developed the manufacturing process for Januvia®, a groundbreaking treatment for Type 2 Diabetes now marketed in over 100 countries.

Learn more about our team: https://t.co/yvMbOpZecw

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

What makes HDAC inhibitors a powerful ally in the fight against cancer? They target enzymes cancer cells rely on—and help make radiation therapy more effective.

At Shuttle Pharma, we’re working to unlock the full potential of this approach.

Learn more: https://t.co/nXgtGnjbVq

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Shuttle Pharmaceuticals is pleased to announce the appointment of George Scorsis as Chairman of the Board of Directors.

Mr. Scorsis, who has served as a director since February 2025, brings over 25 years of executive leadership experience driving growth in highly regulated industries—including biotech, cannabis, alcohol, and energy drinks.

We are honored to have his strategic leadership as we advance the next generation of cancer therapies.

See press release for more details: https://t.co/WrRk82nOPZ

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

The fight against brain tumors demands more than the current standard of care. For patients facing aggressive cancers like glioblastoma, surgery, radiation therapy (RT), and chemotherapy remain the frontline treatments — but too often, they are not enough.

At Shuttle Pharma, we are working to change that.

Learn more about our mission and science at https://t.co/drinmvT3DS.

$SHPH #BTAM

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

May is National Brain Tumor Awareness Month.

Raising awareness is critical to driving progress, advancing research, and supporting the patients and families impacted by this devastating disease.

Today, more than 500 clinical trials are underway to find better treatments for glioblastoma. At Shuttle Pharma, we are proud to be part of the effort to bring new options to patients and families.

Visit https://t.co/drinmvTBtq to learn about our innovative therapies and our fight to change the future of cancer treatment.

$SHPH #BTAM

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Today we announced that we have achieved nearly 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites reporting that the drug has been well tolerated and toxicity no greater than 2 on a scale of 1-5.

We are incredibly encouraged by the expedited progress of our Phase 2 trial and the dedication of our team, clinical partners, and patients who are making this milestone possible. Our objective is to finalize enrollment later this year with follow up and data read out in 2026.

View press release: https://t.co/5ub1rZUN38

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Dr. Alejandro Villagra is a renowned cancer immunologist and expert in tumor immunology, immunotherapy, and epigenetics, and has served as a Scientific Advisor to Shuttle Pharma since 2017.

As a Scientific Advisor, he brings deep insight into cellular signaling pathways and the role of epigenetic modifiers in cancer treatment.

Learn more about our team: https://t.co/yvMbOpZecw

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30pm PT / 5:30pm ET.

Live Webcast: https://t.co/Pv161HbkWv

View press release for full details: https://t.co/fFje7MDzm1

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

We are developing our products with the goal of addressing the unmet need in cancer treatment for a commercially marketable radiation response modifier solution that leads to greater sensitivity of cancer cells to ionizing radiation therapy.

Learn more: https://t.co/drinmvTBtq

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Today we announced the filing of a key provisional patent application with the United States Patent and Trademark Office (USPTO) entitled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” The filing comes through Shuttle Pharma’s collaboration with internationally renowned medicinal chemist, Dr. Alan Kozikowski.

We look forward to the continued advancement of our Shuttle Diagnostics’ subsidiary and the opportunity to develop a theranostic that has the potential to play a significant role in the future diagnosis and treatment of prostate cancer.

View press release: https://t.co/adBOtXLY8v

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

We’re pushing the boundaries of what’s possible in cancer treatment. Discover how innovation, dedication, and cutting-edge science are transforming patient outcomes and shaping the future of care.

Join us in our fight against cancer and follow us for recent news and updates on Ropidoxuridine's clinical trial.

Follow us on LinkedIn: https://t.co/AWrUqV3kD7

Sign up for email alerts: https://t.co/2cvgxz5uJT

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Today we announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company’s capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company’s Board of Directors, will continue in his role as Co-CEO overseeing the Company’s scientific and clinical trial activities.

Read the full press release for more information: https://t.co/H5aAyC4xik

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Dr. Weichselbaum is a pioneering leader in cancer research, renowned for his work in radiotherapy, and has served as a Scientific Advisor to Shuttle Pharma since 2013. He is the Daniel K. Ludwig Professor and Chairman of the Department of Radiation and Cellular Oncology at the University of Chicago, a position he has held since 1985.

Driven by a commitment to innovation in cancer care and research, Dr. Weichselbaum continues to shape the future of cancer therapy.

Learn more: https://t.co/yvMbOpZecw

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Today we provided a corporate update along with our 2024 results.

This past year has been highlighted by numerous scientific developments, including the launch of our Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma and substantial progress in advancing our diagnostic subsidiary where our approach is to offer prognosis and guide treatment decisions, with the goal of providing clinicians and patients with a means of measuring the potential for success of radiation therapy for their cancer treatment.

2025 is set to be a year of scientific milestones. We look forward to the continued progress made as we aim to improve the lives of millions impacted by cancer and bring hope to patients and families around the world.

Read our press release for more details: https://t.co/c0qGCI3wTw

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

At Shuttle Pharmaceuticals, we are leveraging our platform technology to discover novel small molecules to modify the effects of ionizing radiation on cancer cells. We have developed a strong portfolio of patented selective histone deacetylase (HDAC) inhibitors and radiation sensitizers.

Explore our pipeline: https://t.co/GRfpcPtak9

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

We are excited to announce the launch of our redesigned website. Discover how Shuttle Pharmaceuticals is leading the way in cancer treatment with next-generation radiation oncology innovations. Explore the latest in our research, therapies, and breakthroughs designed to improve patient outcomes.

Visit now: https://t.co/drinmvTBtq

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

Dr. Mira Jung is a co-founder of Shuttle Pharma and has served as Chief Scientific Officer for Biology since our formation in December 2012. She was also a member of our board of directors from 2012 until 2019. Since 2004, Dr. Jung has been a Professor of Radiation Medicine and Microbiology at Georgetown University Medical School.

Learn more about our management team: https://t.co/LcOdIo6udt

$SHPH

[Shuttle Pharmaceuticals (Nasdaq: SHPH) @shuttlepharma]

At Shuttle, our mission is to launch the next generation of radiation oncology treatments with the goal of curing cancer.

With this goal, we are setting out to accomplish something that has never been done before. We acknowledge that this will not be an easy task and will require dedication, extreme effort, and expertise.

By working together as a team, we believe we can make a meaningful impact and improve the lives of millions affected by cancer.

Learn more at https://t.co/drinmvT3DS

$SHPH